Journal
IMMUNOLOGY LETTERS
Volume 162, Issue 1, Pages 59-67Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.imlet.2014.07.004
Keywords
Dendritic cell; Targeted vaccines; Nanoparticles
Categories
Funding
- NIH [CA135110, CA106802, A1079222]
- Dana Foundation
- Multiple Myeloma Research Foundation
Ask authors/readers for more resources
Dendritic cells (DCs) provide a critical link between innate and adaptive immunity. The potent antigen presenting properties of DCs makes them a valuable target for the delivery of immunogenic cargo. Recent clinical studies describing in situ DC targeting with antibody-mediated targeting of DC receptor through DEC-205 provide new opportunities for the clinical application of DC-targeted vaccines. Further advances with nanoparticle vectors which can encapsulate antigens and adjuvants within the same compartment and be targeted against diverse DC subsets also represent an attractive strategy for targeting DCs. This review provides a brief summary of the rationale behind targeting dendritic cells in situ, the existing pre-clinical and clinical data on these vaccines and challenges faced by the next generation DC-targeted vaccines. (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available